Fig. 4.

RA-Crabp1 modulates exosome secretion via the MAPK kinase pathway. a Western blot analyses using antibodies against RIP140 and flotillin to examine the medium of ESC cultured with RA (100 nM) or control (Ctrl). b Western blot analyses of HT22 culture medium, in cultures pre-treated with 1 µg/ml ACD or 10 µg/ml CHX 1 h, and followed by 100 nM RA treatment. ACD: actinomycin D, CHX: cycloheximide. c Western blot analyses of HT22 culture medium, in cultures pretreated with 100 nM AGN 1 h, and followed by 100 nM RA treatment. AGN: AGN 193109. d Western blot analyses of HT22 culture medium, in cultures pretreated with 10 µM GW 1 h, and followed by 100 nM RA treatment. GW: GW4869. e Western blot analyses, using antibodies against RIP140 and CD9 of medium collected from HT22 culture pretreated with 10 µM U0126 for 1 h, followed by 100 nM RA treatment. f Western blot analyses of medium collected from HT22 culture treated with 100 nM RA, C3 or C4. C3: compound 3; C4: compound 4, chemical names are provided in materials and methods. g A model for RA-Crabp1 action in negatively regulating RIP140-containing neuronal exosome secretion to modulate inflammation. Created with https://BioRender.com